ReviewCell2020
Emerging Pandemic Diseases: How We Got to COVID-19.
Review in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 282 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
282 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Systematic Review and Meta-Analysis of Emerging Viral Zoonotic Diseases, 2016-2026.Transboundary and emerging diseases · 2026Pooled it
- Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysis.Journal of global health · 2025Pooled it
- Internet-based Surveillance Systems and Infectious Diseases Prediction: An Updated Review of the Last 10 Years and Lessons from the COVID-19 Pandemic.Journal of epidemiology and global health · 2024Pooled it
- Major bat-borne zoonotic viral epidemics in Asia and Africa: A systematic review and meta-analysis.Veterinary medicine and science · 2022Pooled it
- Changes in alcohol use during COVID-19 and associations with contextual and individual difference variables: A systematic review and meta-analysis.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022Pooled it
- A need for null models in understanding disease transmission: the example of Mycobacterium ulcerans (Buruli ulcer disease).FEMS microbiology reviews · 2022Pooled it
- Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.Critical care (London, England) · 2024Trial
- Special Issue "Antiviral Drugs Discovery".International journal of molecular sciences · 2026Article
- Extracellular Vesicles as Molecular Regulators of Viral Infection: Implications for COVID-19 and Future Viral Pandemics.Current issues in molecular biology · 2026Review
- Global Viral Lower Respiratory Disease Episodes, Hospitalisations, and Clinical Outcomes by Aetiology, 2010-2021.Infectious diseases and therapy · 2026Article
- Remdesivir from failed Ebola drug to first FDA-approved COVID-19 antiviral: The medico-legal integration.iScience · 2026Review
- Commensal bacteria inhibit viral infections via a tryptophan metabolite.Nature communications · 2026Article
- Mechanics of pandemics.EClinicalMedicine · 2026Review
- Emerging Viral Zoonoses: Epidemiology, Vaccination Strategies, and Implications for Global Public Health.Vaccines · 2026Review
- Pseudovirus-mediated proximity labeling identifies candidate host cell membrane proteins involved in viral attachment.Journal of virology · 2026Article
- Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics.Journal of virology · 2026Review
- Virome diversity, evolution, transmission networks, and zoonotic potential of wildlife on the Qinghai-Tibet plateau.NPJ biofilms and microbiomes · 2026Article
- Glycyrrhizic Acid-Modified Gold Nanoparticles Show Inhibitory Activity Against PRRSV and SARS-CoV-2 Pseudovirus In Vitro.Viruses · 2026Article
- Rapid and potent induction of protective mucosal immunity against SARS-CoV-2 by an adenovirus-vectored nanoparticle vaccine.Journal of nanobiotechnology · 2026Article
- Intranasal Vaccine Adjuvants and Delivery Platforms: From Barrier Mechanisms to Clinical Translation.Vaccines · 2026Review
222 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases prevalent in humans and animals are caused by pathogens that once emerged from other animal hosts. In addition to these established infections, new infectious diseases periodically emerge. In extreme cases they may cause pandemics such as COVID-19; in other cases, dead-end infections or smaller epidemics result. Established diseases may also re-emerge, for example by extending geographically or by becoming more transmissible or more pathogenic. Disease emergence reflects dynamic balances and imbalances, within complex globally distributed ecosystems comprising humans, animals, pathogens, and the environment. Understanding these variables is a necessary step in controlling future devastating disease emergences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.